Ocular Changes in Vitiligo Patients on Therapy

NCT ID: NCT05335746

Last Updated: 2022-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-10

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitiligo patients on systemic and local therapy may have some ocular adverse effects associated with the disease and its therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chorioretinal changes associated with vitiligo therapy could address patients visual acuity and life style. Early detection of these changes can help these patients to evade such adverse effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo Chorioretinopathy Chorioretinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitiligo patients on therapy

Patients diagnosed as vitiligo and on systemic and local therapy.

Optical coherence tomography angiography (OCT-A)

Intervention Type DIAGNOSTIC_TEST

Optical coherence tomography angiography scanning will be done for all subjects in the study.

Control group

Normal subjects recruited from ophthalmology clinic and visit the clinic for regular check-up.

Optical coherence tomography angiography (OCT-A)

Intervention Type DIAGNOSTIC_TEST

Optical coherence tomography angiography scanning will be done for all subjects in the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optical coherence tomography angiography (OCT-A)

Optical coherence tomography angiography scanning will be done for all subjects in the study.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OCT-A

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* vitiligo patients on systemic and local therapy that regularly visit dermatology clinic at banha university.
* normal subjects seeking regular ophthalmic examination at ophthalmology clinic at banha university.

Exclusion Criteria

* patients with known chronic retinal diseases that may alter OCT-A parameters as age related macular degeneration and diabetic retinopathies.
* patients that refuse to participate in this study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Benha University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Abdelshafy

Clinical professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amal A Yousif, MD

Role: PRINCIPAL_INVESTIGATOR

Benha University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Benha University

Banhā, QA, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ahmed Abdelshafy, MD

Role: CONTACT

01222328766

Amal Yousif, MD

Role: CONTACT

01008128810

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ahmed Abdelshafy, MD

Role: primary

01222328766

Amal Yousif

Role: backup

01008128810

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Rc 6-2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Wide Field OCTA in Ocular Diseases
NCT07298174 NOT_YET_RECRUITING